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ABSTRACT 
 
 
Synthesis of Pyrimidine C-Nucleoside Analogues and Triphosphate Derivatives 
Heng Ming Chan 
 Five pyrimidine C-nucleosides were prepared via Heck-type coupling reactions. 
These derivatives are designed to mimic dC and dU (or T). The minor groove O2 
carbonyl in each derivative is replaced by a hydrogen, a fluorine, or a methyl group. The 
hydrogen-substituted dC analogue was converted into a 2’,3’-dideoxynucleoside, which 
was converted into a 5’-triphosphate derivative. The other two dC analogues were 
transformed into 5’-triphosphate derivatives immediately after Heck coupling reactions. 
These analogues will allow an examination of the nature and role of minor groove 
interactions between incoming triphosphates and various polymerases.   
 
 
 
 
 
 
 
 
 
 
 
 
                            
Introduction 
Most organisms rely on accurate replication of the individual genome to survive 
and continue life. It was only 55 years ago when 2’-deoxyribonucleic acid (DNA) was 
proved to contain the genetic information1 and that DNA polymerases were responsible 
for making copies of the genome.2 DNA replication allows subsequent events such as 
transcription and translation for cellular construction and biological activities. For over a 
half century, a continuous flow of research papers have uncovered many details of this 
enzyme-mediated process, attempting to put all the pieces of the puzzle together. 
Structural understanding of the DNA base pairs, the duplex and the polymerases provide 
a basis for our investigation of this mechanism.  
Natural DNA base pairs are held together by hydrogen bonds. The heterocycles of 
natural nucleosides provide specific arrangement of hydrogen bond donors and acceptors, 
which allows pairing specificity of base pairs. Adenine matches only with thymine (uracil 
in RNA) via two hydrogen bonds, and guanine is only complementary to cytosine by 
three hydrogen bonds (Figure 1). These bonds are important for holding together two 
complementary strands of DNA chains as discovered by James Watson and Francis 
Crick3 in 1953, hence the name “Watson-Crick hydrogen bonds.” Watson and Crick also 
proposed that the DNA duplex adopts a right-handed helical structure, where the two 
strands are oriented in an anti-parallel fashion. The double helix is often described in 
analogy to a gently twisted ladder, in which the sugar – phosphate backbones on the 
outside are the two rails of a ladder and the bases inside are the rungs as they are co-
planar and stacked on top of each another (Figure 2). Two apparent macroscopic features 
of a DNA (or RNA) duplex are a major groove and a minor groove. Functional groups of 
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the heterocycles facing these grooves, respectively, play essential roles in binding and 
recognition by proteins and small molecules.4 
N
N
NH2
O
N
N
N
N
O
N
H
H
H
N
N
N
N
N
N
N
O
O
H
H H
MAJOR GROOVE
MINOR GROOVE
C : G T : A
 
Figure 1. The complementary base pairs of C-G and T-A. The arches above the base 
airs encompass the functional groups in the major groove and those below encompass 
the functional grooves in the minor groove.  
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Figure 2. DNA duplex represented in ball-and-stick and space filling representations. 
Both the side and top views are shown. Minor and major grooves are indicated by arrows. 
Image adapted from Saenger.4 
 
Several crystal structure analyses of DNA polymerases have revealed that many 
DNA polymerases share the same general multidomain architecture. 5   Polymerases like 
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Escherichia coli DNA Pol I, T7 DNA polymerase, Thermus aquaticus DNA polymerase 
(Taq), and retroviral polymerases such as human immunodeficiency virus reverse 
transcriptase (HIV-RT) have subdomains described as the palm, fingers and thumb 
(Figure 3). These studies also suggested that the polymerases undergo structural changes 
during polymerization. The polymerization process takes place in steps.6 Initially, the 
unliganded polymerase has the thumb subdomain in ‘closed’ position (indicated as E in 
Figure 4).7 It moves the thumb to accommodate a nucleic acid duplex to form a binary 
complex (step 1 in Figure 4).8 The primer terminus of the DNA duplex is positioned at 
the priming site (P site) of the active site, allowing the incoming triphosphate to bind at 
the nucleotide – binding site (N site).6 Upon binding of an incoming dNTP (step 2), the 
fingers subdomain change from open conformation to closed by pressing onto the 
triphosphate (step 3). This conformational change is likely rate determining9 and seems 
to conform to an “induced fit model,” in which the correct nucleotide triggers the enzyme 
to adopt an active configuration.10 The polymerase arranges key residues in the active 
site for stabilizing interactions with the DNA duplex and with the substrate. Many of 
these contacts include those to the minor groove functional groups. In contrast, an 
incorrect substrate results in a poor “fit” into the active site and the conformational 
change is slowed down. A rapid chemistry step follows the conformational change to 
form a new phosphodiester bond accompanied by the release of pyrophosphate as a 
byproduct and possibly opening of the fingers subdomain (step 4). In processive 
polymerization, the polymerase moves onto the next nucleotide on the template by 
translocating the primer terminus to the P site and continue the catalytic cycle (step 5). If 
polymerization is distributive, the enzyme dissociates from the elongated primer/template 
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duplex and the polymerase restarts from binding to a new DNA duplex. The efficiency of 
the primer terminus translocation determines whether the enzyme will continue 
polymerizing or fall off from the nucleic acid.6 It is also associated with the resistance of 
some mutated reverse transcriptases to their inhibitors (will be discussed later).  
 
Figure 3. Closed and open forms of the large fragment of Thermus aquaticus DNA 
polymerase I (Klentaq1). A and C: a ‘closed’ ternary complex structure of Klentaq1 with 
a DNA duplex and a triphosphate substrate. The fingers domain closes the crevice formed 
by thumb, palm, and fingers. B and D: a binary complex without the triphosphate 
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substrate. The fingers domain is in the open form, in which the crevice is clearly visible. 
Adapted from Li, Korolev and Waksman.5b 
 
 
 
 
Figure 4. Schematic representation of the stepwise replication process by a polymerase. 
Only the primer terminus is shown occupying the priming site (P) or the nucleotide-
binding site (N). Step 1: the unliganded polymerase (E) binds to a DNA duplex and 
positions the primer terminus in the P site. Step 2: a nucleotide triphosphate binds in the 
N site to form an “open” ternary complex. Step 3: the enzyme undergoes conformational 
changes to form a “closed” ternary complex. Step 4: a chemical step takes place to form a 
new phosphodiester bond and release inorganic phosphate. Step 5: in processive synthesis, 
translocation happens to place the new primer terminus in the P site to continue 
polymerization. Step 5’: in distributive synthesis, the polymerase dissociates from DNA 
to return to the unliganded state. Adapted from Sarafianos et. al.6 
 
While most DNA polymerases produce DNA copies of the genome according to a 
DNA blueprint, some retroviruses such as human immunodeficiency virus (HIV) contain 
an RNA genome but replicate through a double-stranded DNA intermediate. The enzyme 
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responsible for such reversed transcription is known as a reverse transcriptase (RT). In 
the life cycle of a typical HIV, the retrovirus infects host cells, primarily T-helper 
lymphocytes and macrophages in the immune system. The viral RNA is uncoated in the 
host’s cytoplasm. Reverse transcriptase synthesizes a complementary strand of DNA 
(DNA transcript) based on the RNA template. Then, it digests the RNA genome and 
synthesizes a second strand of DNA that is complementary to the first.11 The double-
helical viral DNA (cDNA) is now available for integration into the host genome. Using 
the cellular resources of the host, new viral RNA and proteins are produced for viral 
assembly and eventual release of the virion.  HIV infection causes acquired immune 
deficiency syndrome (AIDS) and infected individuals could die from collapsed immune 
system. Reverse transcription is the most therapeutically targeted stage in the HIV 
lifecycle because inhibition will prevent the synthesis of cDNA and the ultimate insult.  
 
 
 complementary DNA 
anscript is first synthesized. The template is digested then a second complementary 
DNA s
 
RT 
Viral RNA RNA- DNA 
Digestion 
DNA cDNA 
RT 
hybrid transcript 
Figure 5. Synthesis of cDNA by RT using an RNA template. A
tr
trand is synthesized to make a double stranded DNA copy. 
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A class of modified nucleosides specifically targets the RT; they are called 
reverse transcriptase nucleoside inhibitors (RTNIs).12 Some of them are routinely used in 
the clinical treatment of HIV-infected individuals. They are 2’-deoxyribonucleoside 
analogues without the 3’-OH on the ribose moiety. They include zidovudine (AZT),13 
zalcitabine (ddC),14 didanosine (ddI), stavudine (d4T),15 lamivudine (3TC), and abacavir 
(ABC) (Figure 6). Intracellular conversion to 5’-triphosphate derivatives allows them to 
compete with natural nucleotides for the recognition by reverse transcriptase as substrates. 
When incorporated into nascent viral DNA chain, the NRTIs fail to continue the 
long
term
 
igure 6. Anti-HIV RT nucleoside inhibitors used in clinical treatment of AIDS. 
 
 
 
e ating chain due to the lack of a 3’-nucleophile, so they are also known as “chain 
inators.”  
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Figure 7. Mechanism of nucleoside chain terminators and TAM-associated excision. Top 
panel: dideoxynucleotide is incorporated into primer to form a stable dead-end complex. 
Bottom panel: AZT is excised by dATP or inorganic phosphate and the terminated primer 
is unblocked. Adapted from Goldschmidt and Marquet.16 
 
AZT and other dideoxynucleoside inhibitors take effect by forming a stable dead-
end complex with reverse transcriptase (Figure 7 top). 17  Just as in the insertion 
mechanism discussed earlier, RT inserts the RTNI (ddNTP) into the primer in the N site 
of the active site. The terminal RTNI phosphodiester translocates to the P site to 
accommodate an incoming dNTP. The dNTP occupies the N site and the formation of a 
new phosphodiester bond is precluded by the nature of the RTNI. As a result, the 
polymerase – DNA complex is trapped in a “dead-end” complex and polymerization is 
disrupted. 
The emergence of resistant strains of HIV, however, has enabled two major 
phenotypic mechanisms to hamper the efficacy of the drug.7a,16 The first one is RTNI 
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discrimination, in which the mutant reverse transcriptase preferentially incorporates 
natural nucleotides over synthetic ones. The second involves pyrophosphate or ATP-
dependent phosphorolytic excision of the incorporated RTNI from the 3’-end of the 
primer strand. It is primarily associated with AZT, caused by a set of mutations 
commonly known as thymidine analogue mutations (TAMs) (Figure 7 bottom).18 In the 
case of TAM bearing polymerases, AZT is incorporated into the primer in the N site. 
Because of enhanced affinity for ATP and inorganic pyrophosphate,16 the mutated RT 
binds to either one and the pyrophosphate donor attacks the AZT phosphodiester. The 
AZT phosphodiester is bonded to the ATP to form a dinucleotide polyphosphate or to the 
pyrophosphate to generate AZT triphosphate. In either case, AZT is excised from the 
primer terminus and the initially terminated primer could resume elongation. In this 
regard, patients with resistant strains of HIV show a reduced sensitivity to these 
thymidine analogues.  
Besides the problem of resistance, many existing anti-HIV dideoxynucleosides 
including AZT, ddC, and ddI have shown cytotoxicity effects. Delayed toxicity most 
commonly takes the form of peripheral neuropathy, myopathy, or pancreatitis.19 Kuchta 
and coworkers20 discovered a pathway through which AZT monophosphate accumulates 
and potently inhibits protein and lipid glycosylation in the Golgi complex and 
endoplasmic reticulum. This results in glycolipid composition change in the cellular 
membrane and thereby alters the properties of many receptors and enzymes.21 Anemias 
that result from killing of blood progenitor cells also possibly involve inhibition of 
protein glycosylation. 22  Medina and coworkers 23  compared three anti-HIV dideoxy-
nucleosides ddC, d4T, and ddI and found significant reduction in cell viability and 
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mitochondrial DNA (mtDNA) content as well as mitochondrial morphology distortion in 
treated cultured cells. The damage was proportional to the concentration of the 
nucleosides. The cytotoxicity effects of three were in the order of ddC > D4T > ddI. It 
seems obvious from these studies that interference with cellular polymerases or activities 
adds another challenge to creating clinically practical anti-HIV agents. Scientists have 
developed a wide range of synthetic nucleosides and studied their interactions with 
various polymerases and reverse transcriptases, in order to identify a crucial factor to 
elicit enzyme discrimination.  
Kool and coworkers have introduced a class of nonpolar nucleoside analogues 
and used them to probe minor groove interactions with various polymerases and reverse 
transcriptases. These analogues mimic as closely as possible the size and shape of natural 
nucleosides but have little or no Watson-Crick hydrogen bonding capacity (Figure 8). 
They have been placed in the template of an incipient base pair and used as triphosphate 
substrates with various polymerases and reverse transcriptases.24  These enzymes were 
grouped into three based on the number of minor groove interactions. The first group 
efficiently replicated base pairs containing F and Z: the exonuclease-free Klenow 
fragment (KF-), exonuclease-inactive T7 polymerase (T7-), Taq polymerase, and HIV-
RT. They do not seem to require any contacts between amino acid side chains at the 
active site and the minor groove side of the incipient base pair. Available crystal 
structures of some of these enzymes complexed with double stranded DNA and a 
nucleotide supported this.25 The second group of polymerases consisted of calf thymus 
DNA polymerase α (Pol α) and avian myeloblastosis virus reverse transcriptase (AMV-
RT), which required a minor groove interaction at either the template base or the 
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incoming triphosphate. The last group formed by human DNA polymerase (Pol β) and 
Moloney murine leukemia virus reverse transcriptase (MMLV-RT) failed to replicate any 
of the nonpolar base pairs, suggesting that these enzymes possibly require minor groove 
interactions at both the template base and the incoming nucleotide simultaneously for 
efficient replication. This study of nucleotide-protein interactions at the insertion step 
demonstrated the plausibility of using base-modified analogues to target HIV-RT but 
leave out eukaryotic polymerases such as Pol α and Pol β. 
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Figure 8. Kool’s hydrophobic isosteres. 
 
More importantly, these nonpolar isosteres have established that shape 
complementarity (avoidance of steric clashes) plays a critical role in DNA replication.26 
Kool and coworkers demonstrated that the hydrophobic analogue F is inserted across 
from A with an efficiency nearly the same as that of a T-A pair.27 F is also replicated 
efficiently and selectively against two adenine shape mimics Z and Q in vitro and in vivo, 
respectively.25 Kool advocates that shape complementarity is a stricter requirement than 
the need for Waston-Crick hydrogen bonds in polymerase-catalyzed base pair 
synthesis.28 He reinforces this idea using a steric exclusion hypothesis to explain how a 
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geometrically disfavored base pair would result in exclusion from the active site of a 
polymerase (Figure 9). The active site of the polymerase is defined by the enzyme itself 
and the incipient base pair enclosed. With natural nucleotides alone, there may be four 
possible sizes and shapes for the active site cavities during each successive nucleotide 
insertion, one per each of the four natural bases. The polymerase excludes purine – purine 
pairs simply because they are too large to fit in the binding pocket together (case 2). The 
enzyme also avoids inserting an incorrect pyrimidine opposite a given purine because of 
a proton – proton steric clash when C is across from A or T from G (case 3).  
In the case of a pyrimidine – pyrimidine mismatch, both relatively small 
nucleotides can fit in the binding pocket, but solvation effects prevent such misinsertion 
(case 4). Both pyrimidines can form hydrogen bonds with water molecules through their 
Watson-Crick hydrogen bonding groups. The solvating waters can exchange with each 
other, but they will effectively never be lost in the aqueous environment. They are 
energetically favorable with a calculated free energy range of -3.7 to -14.5 kcal/mol.29 A 
single water adds about 3 to 4 Å of steric bulk to the Watson – Crick edge of each 
pyrimidine.30 This makes the effective size of a pyrimidine large enough to be excluded 
from the active site. The pyrimidines will not exchange the waters to bind with each other 
because of two possible reasons: 1) hydrogen bonds are strong (several kcal/mol) so 
desolvation of two bases would be highly costly, and 2) even if desolvation did occur, the 
two bases would have to achieve complementarity by altering the geometry (as in T-T 
wobble pair), resulting in steric clashes with the walls of the enzyme active site. Similar 
effects would be operative for pyrimidine – purine and purine - purine mispairs. Thus, 
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steric effects enforce shape complementarity of a base pair in the active site and solvation 
effects enhance these steric effects. 
  
 
 
 
 
 
 
 
 
 
 
N
N
NH2
O
N
N
N
N
O
N
CASE 1: pyr - pur complementary pair
N
N
N
N
O
N
CASE 2: pur - pur mismatched pair
N
N
N
N
O
N
H
H
H
H
H
H
H
H
H
N
N
N
O
N
N
N
N
N
CASE 3: pyr - pur mismatched pair
H
HH
H
N
N
N
O
CASE 4: pyr - pyr mismatched pair
N
N
O
O
H
H
H
 
Figure 9. Representation of matched and mismatched pairs in the active site of the 
polymerase. Steric clashes in cases 2-4 could lead to exclusion of mismatches. Water 
molecules are shown hydrogen bonded to one pyrimidine in 4.28  
 
 
The McLaughlin group reported two pyrimidine nucleoside analogues, d*C and 
d*T (Figure 10) that also mimicked the shape of a natural base, but selective removal of 
the minor groove functional group seemed to cause inhibitory effects toward polymerases 
KF and Taq.31 Two of the Watson-Crick hydrogen bonds of the pyrimidine bases are 
reserved to take advantage of the high cost of desolvation in the case of mismatched pairs. 
Direct elimination of the minor groove O2 carbonyl resulted in attendant changes of the 
hydrogen-bonding character of the N3-nitrogen. The presence of this analogue in DNA 
results in significant duplex destabilization. 32  By preparing the corresponding C-
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nucleosides,33  however, the correct tautomeric forms of the bases are maintained for 
proper Watson-Crick-like hydrogen bonds. Syntheses of C-nucleosides have been well 
explored.34 Most naturally occurring C-nucleoside compounds are antibiotics and many 
also possess antiviral and/or antitumor properties.35 
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Figure 10. Nucleoside analogues used in McLaughlin’s studies. 
 
The triphosphate derivatives d*CTP and d*TTP were found to inhibit the Taq 
polymerase under standard PCR conditions.31 The experiments were repeated with KF 
and progressive concentration-dependent suppression of full-length products was 
confirmed. These results indicated that pyrimidine nucleotides lacking the 2-keto group 
are poor substrates for Taq and KF. The keto group seems to assist interactions between 
the incoming triphosphate and some amino acid side chains in the active site of the 
polymerase in order to correctly position the incoming triphosphate for proper alignment 
with the primer terminus. Without the keto group, however, the unnatural triphosphate 
may be placed in the active site in a position where necessary conformational change of 
the enzyme fails to permit formation of a phosphodiester bond and release of 
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pyrophosphate. Therefore, the deletion of the minor groove carbonyl group seems to have 
given rise to the inhibitory effect of these derivatives.  
Upon this finding, the McLaughlin group went on the produce a 
dideoxynucleoside triphosphate dd2APyTP (Figure 10) that showed substrate activity 
with HIV RT but discriminated against polymerases α, β, and to some extent γ.36 The 
design of the cytidine analogue d2APy combines two advantageous features: the 2’,3’-
dideoxy carbohydrate moiety will ensure chain termination and the heterocyclic 
nucleobase without the minor groove O2 carbonyl group may elicit enzyme 
discrimination. In a 45-minute time course assay, no significant elongation of the primer 
strand was observed for DNA Pol α or β at dd2APyTP concentration as high as 1mM, 
while it only took low µM concentration of the natural nucleotide for the same elongation 
to occur. On the other hand, mitochondrial polymerase (Pol γ) extended roughly 11% of 
the primer in the presence of 100 μM dd2APyTP and HIV RT 50% under the same 
conditions. Since most cytotoxicity instances involve the mitochondrial polymerase using 
the chain terminator for mitochondrial DNA replication, the enzyme was incubated with 
dd2APy-incorporated DNA to estimate the cytotoxicity effect. The rate of Pol γ removing 
the dideoxynucleotide by exonuclease activity was commensurate with that of 3TC and 
significantly faster than that for ddC.37 That means the dideoxynucleotide cytotoxicity 
level was well tolerated if not better than the clinically approved chain terminators. Thus, 
dd2APy presents a selective antiviral prodrug with limited cytotoxicity. Kinetic data 
remain yet to be obtained to determine the insertion efficiency for this particular substrate. 
Since the extent of shape alteration arising from the complete deletion of the 
pyrimidine minor groove functional group remains unclear, substitutions in the minor 
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groove region with fluorine and a methyl group may help examine the nature of minor 
groove interactions between the HIV-RT and the nucleotide. We have replaced the O2 
carbonyl with a fluorine (FAPy and F62P) or a methyl group (m6APy and m62P), in 
addition to the previously mentioned hydrogen-substituted analogues d2APy and d*T 
(Figure 11). The methyl group in the fifth position of thymine will be deleted for the 
simplicity of synthesis because its distance from the minor groove region should diminish 
any effect on minor groove interaction. The previously discussed thymidine analogue, 
difluorotoluene (F),23,25,26 also contains a fluorine substitution in the minor groove region. 
Its specific insertion across adenine by KF might have been made possible by fluorine-
hydrogen bonds, besides the fact that F is a good shape mimic of T. In addition, fluorine 
may also replicate the electron-withdrawing effect of a carbonyl group, making it an 
electronic mimic of the carbonyl. It remains to be determined whether the F-A pair is a 
result of shape complementarity, electronic effect, fluorine-hydrogen bonding, or a 
combination of all. Nonetheless, F represents a successful example of polymerase 
substrates FAPy and F62P nucleosides may possess the same advantages. Furthermore, 
FAPy nucleotide has been incorporated into a DNA duplex to probe interactions with a 
minor groove binding molecule.38  The presence of single fluorine in a DNA duplex 
appears to promote helix stabilization and native-like stabilization occurs when both 
fluorines are present. These interactions are likely the sum of fluorine-hydrogen bonding 
and dipole-dipole or dipole-quadrupole interaction. The methyl substitution in the minor 
groove may be compared to a thiocarbonyl replacement in the same position39 because 
they both increase the size of the thymine base by a small increment (the thiocarbonyl is 
0.45 Å longer than the carbonyl). The 2-thiocarbonyl-substituted thymidine analogue 
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demonstrated that the modification stabilizes a duplex better than the natural congener 
and that it base pairs with A with high selectivity. The methyl group of m6APy and m62P 
nucleosides might also provide similar base pairing selectivity by size exclusion and 
possibly hydrophobic interactions with the polymerase active site. Even if the methyl-
substituted nucleotide is not a polymerase substrate, the results may have implications on 
the size or electronic requirement for base pair synthesis.  
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Figure 11. Modified nucleobases of target molecules compared to natural pyrimidine 
bases.  
 
 
 
 
Figure 12. Product of Heck coupling reactions differ from natural and dideoxy 
nucleosides in the substitution at the 3’ position of the carbohydrate.  
 
The current work will present a convergent synthetic scheme for the precursors of 
the dideoxynucleosides. The precursors are the products of a popular C-nucleoside 
Heck coupling product
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preparative approach – the Heck coupling reaction (Figure 12). Since they also lack the 
3’-OH, they are technically chain terminators just as the dideoxy derivatives. The 
presence of a carbonyl at the 3’ position of the carbohydrate moiety could be constructive 
because it may better imitate the 3’-OH group than a hydrogen in terms of bond length 
and polarity, although the geometry of the 3’-carbon is sp2 in place of sp3 (Figure 12). 
The 3’-OH group was found important during base pair synthesis by KF - a Phe762 side 
chain of the active site makes a snug fit that constrains the deoxyribose into the correct 
position for the 3’-OH to make contact.40 This interaction contributes to the setup of the 
three-dimensional arrangement for proper conformational change of the enzyme just prior 
to phosphodiester bond formation. The triphosphate syntheses of dd2APy and Heck 
coupling products with bases of FAPy and m6APy will be included in the end of this 
paper. These triphosphate derivatives will allow future research on their polymerase 
activities and chain-terminating ability.  
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Results and Discussion 
 
The synthesis of the C-nucleosides involves a Heck-type coupling reaction1 to 
connect a sugar bearing a double bond and an iodo-heterocycle. The coupling reaction 
generates a carbon-carbon glycosidic bond, which helps maintain the correct tautomeric 
form of the heterocycle for Watson-Crick-like hydrogen bonding. The versatility of this 
palladium-mediated Heck-type coupling reaction provided convergence of these 
syntheses and convenience in preparation. The same double-bond-bearing carbohydrate 
can react with a number of similar iodo-heterocycles under the same conditions to 
produce a series of C-nucleosides.2  Each reaction yielded only the β anomer in part 
because a bulky silyl protecting group on the carbohydrate precludes addition of the 
heterocycle on the bottom face of the double bond. The sugar portion was prepared as 
follows (Scheme 1).3  
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Preparation of the Carbohydrate 
The goal was to make the α face of carbohydrate sterically hindered. Here we 
employed extremely bulky and different protecting groups to provide selectivity and 
stability. Beginning with commercially available thymidine, the stereocenters on the 
carbohydrate are already set. Taking advantage that a primary hydroxyl group is more 
reactive than a secondary one, we protected the 5’-hydroxyl group with 1.1 equivalent of 
DMTr-Cl. After activation with DMAP, the dimethoxytrityl group was installed mostly 
on the 5’-O position, although a small amount of thymidine simultaneously protected at 
the 5’- and 3’-O positions was also observed. The excess DMTr reagent was quenched 
using methanol. For workup, either dichloromethane or diethyl ether could be used in 
combination with water. When dichloromethane was used, all DMTr-containing 
compounds remained in the organic layer. When diethyl ether was used, however, all the 
DMTr-containing compounds were in the organic layer but the desired 5’-O protected 
thymidine could be precipitated out of the crude mixture. The pure, white solid product (2) 
was filtered. Sometimes sodium sulfate triggered the precipitation during drying after 
extraction. The drying agent could be removed and washed with dichloromethane to 
redissolve any trapped product. When precipitation did not happen at all, the mixture was 
separated on a silica gel column using a small percentage of triethylamine to protect the 
acid-sensitive dimethoxytrityl.  
In the second step, tert-butyldiphenylsilane was chosen to protect the 3’-OH for a 
couple of reasons. First, the protecting group is extremely bulky so the bottom face of the 
sugar will be blocked completely to allow coupling reaction to occur exclusively on the 
other face. Second, this silane group is acid stable so the 5’-O-DMTr group can be 
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removed selectively as it is in the next step. The workup of this reaction was often a 
simple dichloromethane and water extraction; no column was necessary as long as the 
starting material was pure and completely consumed. 
To remove the 5’-O-DMT group in the third step, we often used p-toluenesulfonic 
acid. Although this reaction should be done within a half hour according to the reported 
procedure, p-toluenesulfonic acid often needed to be added in a few portions over a time 
period of up to two hours. It was found that adding a small amount of methanol initially 
helped speed up the reaction because methanol quenches the DMT cations to generate 
DMTr-OCH3, favoring deprotection. A couple of aqueous base washes were often 
performed to neutralize any acid before column purification; the silane group is unstable 
in acid over extended period of time. For the column, ethyl acetate and hexanes provided 
a better solvent system than methanol and dichloromethane.  
For the last step to synthesize the sterically hindered sugar 5, thymine was 
eliminated as a fully silylated heterocycle. 1,1,1,3,3,3-hexamethyldisilazane (HMDS) in 
the presence of ammonium sulfate reacted with all the oxygen functional groups on 
thymine as oxygen has strong affinity for silicon. Such protection resulted in a positively 
charged glycosidic nitrogen. Removal of a 2’-proton cleaves the glycosidic bond and 
relieves the positive charge of that nitrogen. This elimination reaction was very 
temperature-sensitive. It required a reaction temperature of at least 140°C. When the 
mixture was refluxed at only 130°C, not all protected base was removed. The workup for 
this reaction was modified to improve yield. The old procedure called for a water wash 
after evaporating the HMDS. This caused serious emulsion and the separation of the two 
layers was overly time-consuming. This wash was omitted completely. To remove the 5’-
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O-silyl group on the sugar moiety, methanol was added directly to the concentrated crude 
mixture to create a white suspension. The solid was possibly from HMDS precipitate in 
methanol. Fine powder of K2CO3 was added and the reaction was over within half an 
hour. The old procedure called for a brine wash after removing methanol and it caused 
the same problem as did the earlier water wash. This wash was omitted as well. The 
excess K2CO3 and the precipitate were filtered together through a thin layer of Celite. The 
filtrate was a clear solution and concentrated for column purification immediately. The 
product was easily eluted with straight dichloromethane. The 3’-O-TBDPS group was 
intact.  
 
Heck-Coupling Reactions 
While 2-amino-5-iodopyridine was commercially available, the other iodo-
aromatic compounds were synthesized by a former graduate student, Dr. Zhenhua Sun.3 
An undergraduate student, William Issa, reproduced these procedures and contributed the 
heterocycle derivatives to the following coupling reactions. The carbonyl of uracil 
analogues was protected as p-nitrophenylethylether (pNPE). 
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Scheme 2  
 
 
 
The carbohydrate is coupled with various iodo-substituted heterocycles to 
generate the corresponding C-nucleosides using a palladium catalyst (Scheme 2 & Figure 
13). The catalyst mixture is usually freshly prepared by combining palladium (0) and 
pentafluorotriphenylphosphine in acetonitrile. The color of the mixture turns from black 
to orange brown, indicating the readiness of the catalyst. Oxidative insertion of the metal 
into the carbon-iodide bond of the heterocycle initiates the coupling cycle.  Palladium is 
activated from the ground state to a palladium (II) species. Addition of the carbohydrate 
allows π - complexation between the Pd (II) complex and the olefin. The electron-rich 
heterocycle tends to bond with the relatively electron poor anomeric carbon and 
palladium (II) tends to go onto the relatively electron rich 2’-carbon of the carbohydrate. 
The resulting complex is sometimes called a sigma-adduct as a new sigma bond is 
formed. The sigma-adduct then decomposes preferably by syn-elimination of a β-hydride 
and palladium, generating the coupled product with a new π bond between the 2’ and 3’ 
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carbons of the carbohydrate. The catalyst is regenerated by reductive elimination; a base 
added to the reaction mixture removes the 3’-proton and halide to give the Pd (0) species 
again. The catalyst then can be reactivated and reentered into the coupling cycle.  
 
N
NH2
I
Pd0L2
Oxidative
Addition
N
NH2
PdII
L L
Pi-Complexation
N
NH2
PdII
I
L
Sigma-adduct
Formation
Beta-hydride
Elimination
N
NH2
I
L
H-PdIIL2I
Reductive
Elimination
HI/Base
Base
O
OTBDPS
HO
O
OTBDPS
HO
O
OTBDPS
HO
O
TBDPSO
H PdIIL2I
N
NH2
HO
H
 
 
Figure 13. Mechanism of Heck coupling reaction. 
 
 
The 2-aminopyridine derivative 6 had been synthesized successfully in our 
laboratory.4 The results were reproducible and gave the desired product in good yield. 
For this reaction, the iodo-heterocycle was commercially available and so was sometimes 
used in excess. The proportion of the sugar to heterocycle was either 1 to 1 or 1 to1.5; 
extra heterocycle did not seem to help drive the reaction to completion. The catalyst  
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bis(dba)palladium(0) or tris(dba)dipalladium (0) made no difference in reaction condition 
or results (dba is a ligand: dibenzylideneacetone). When the reaction mixture was kept 
anhydrous and oxygen-free, the yield reached above 80 % easily.  
Coupling reactions for the other C-nucleosides 7 – 10 seemed more sensitive to 
changes in reaction conditions. Deviations from the original procedures published by Dr. 
Zhenhua Sun3 revealed more findings about this reaction, although yield was not 
necessarily enhanced. When the coupling reaction was first attempted for the 2-
aminopyridine derivative 6, 10 % pentafluorotriphenylphosphine ligand was first used for 
10 % of tris(dba)dipalladium (0) in the reaction mixture. This resulted in very poor yield 
because the activated palladium (II) species required two neutral ligands, both of which 
may be phosphine. That is, 10 % of pentafluorotriphenylphosphine provided only 2.5 % 
of activated Pd (II) species after oxidative insertion. The yield was bound to be 
unappreciable due to the reduced amount of catalyst. Therefore, at least 20 % of the 
phosphine ligand was required for 10 % of the palladium catalyst.  
Unlike the commercially available 2-amino-5-iodo-pyridine, all the other 
heterocycles were synthesized in the laboratory. The iodo-aromatic compounds were 
more precious compared to the carbohydrate, which can be produced in bulk for a large 
number of reactions. The heterocycle was therefore chosen to be the limiting reagent in 
the coupling reactions for 7 - 10 and the decision has proven wise. A general trend 
observed for these coupling reactions was that when the sugar was made in excess rather 
than the limiting reagent, the yield was also enhanced probably for a couple of reasons. 
First, this increases the chance of the sugar reacting with a palladium-inserted heterocycle 
complex at the beginning of the coupling cycle. Second, since the sugar decomposes at 
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elevated temperature over a prolonged period of time as this reaction requires, the rate of 
the reaction is made more competitive with the rate of decomposition by guaranteeing a 
surplus of that sugar.  
Another observation was that higher reaction temperature dramatically improved 
yield. When the reaction mixture for synthesizing 8 was prepared as reported, refluxing at 
55°C yielded only 3.6 % of the desired product. When the temperature was increased to 
85°C, however, the yield was increased by about 15 fold (59 %). Higher temperature was 
probably increased the rate of the β-hydride elimination step.  
Removal of the 3’-O-TBDPS group of the direct products from the coupling 
reactions provided nucleosides 6 -10. The 2-aminopyridine nucleoside 6 was selected to 
convert into a dideoxy derivative. Two methods were attempted and both of them 
provided mild alternatives to standard Wolf-Kishner deoxygenation.5 The first involves a 
tosylhydrazone intermediate and the second a dithioketal intermediate. Both employ 
reductive conditions to reduce the carbonyl of the sugar moiety into a methylene group. 
 
Preparation of 2’,3’-dideoxy-2-amino-pyridine (dd2APy) 
 The first route was reported by a former graduate student, Dr. Dongli Chen, in our 
laboratory (Scheme 3).4a He first converted 6 into a tosylhydrazone derivative 11 then 
used sodium triacetoxyborohydride [Na(OAc)3BH] to reduce the hydrazone into the 
dideoxy nucleoside by stirring at ambient temperature for one hour. Six equivalents of 
sodium borohydride (NaBH4) instead of a larger equivalent of the less reactive 
Na(OAc)3BH were used to completely consume the starting material. In fact, NaBH4 in 
acetonitrile and acetic acid generates Na(OAc)3BH in situ6so either hydride source could 
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be used. The immediate product of this reduction step was not the desired dideoxy 
product. The Rf value of that compound was apparently distinct from that of the starting 
material. It was determined by 1H NMR and mass spectral analysis to be a tosylhydrazide 
resulting from the direct reduction of the C-N double bond. Since the reported procedure 
did not give the final product, what more needed to be done to further reduce the 
hydrazide?  
 
Scheme 3 
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A few literature references provided some mechanistic details.5a,7 The reduction 
reaction proceeds in two stages: reduction to an intermediate which is then decomposed 
(Scheme 3). A tosylhydrazone is first reduced into a tosylhydrazide by hydrides such as 
NaBH4 (Figure 14 A). Little hydrocarbon product is detected until the mixture is heated 
under reflux with water to yield a diazene intermediate, which then decomposed. Both 
the tosylhydrazide and diazene intermediates were detected using mass spectral analysis 
(Obs. 379.1430 for tosylhydrazide and 223.1205 for diazene) after heating for a short 
time. Two mechanisms have been proposed to account for the diazene decomposition.8 
The first is a chain reaction involving traces of oxygen or other oxidizing impurities 
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(Figure 14 B). A radical is first generated at the terminal nitrogen. Upon releasing a 
nitrogen gas molecule, an alkyl radical is generated, which then can be quenched by a 
hydrogen radical donor. The second mechanism requires the presence of a base (Figure 
14 C). The base reversibly deprotonates the terminal nitrogen to give a diazenyl anion. 
Formation of a nitrogen gas molecule results in an alkyl anion. A proton transfer offers 
the saturated product. In either mechanism, thermal decomposition produces N2, p-
toluenesulphinic acid and alkane. In addition, the two hydrogen atoms of the methylene 
originate one from the reducing hydride and the second from the NH of the 
tosylhydrazone or from the water during workup.  
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Figure 14. Mechanism of reduction and decomposition of tosylhydrazone to give dd2Py 
nucleoside. (A) Formation of the diazene intermediate. (B) and (C) are two proposed 
mechanism for the decomposition of the diazene to dideoxynucleosides dd2APy. 
 
 
The right amount of heat was crucial for the reduction of the tosylhydrazide 
nucleoside. Without isolating the tosylhydrazide intermediate, solvents were removed on 
high vacuum to give an oil or a foam. Heating of that residue in ethanol at 65°C for an 
hour did not give the desired product. Further heating failed to show any change. It was 
later found that the tosylhydrazide intermediate had decomposed in the hot water bath of 
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the rotorvap! At elevated temperature, side reactions quenching the radical or anionic 
intermediates must have resulted in undesirable products, so subsequent heating of these 
unknown compounds failed to offer the desired dideoxy nucleoside. The temperature of 
the water bath for removing solvents must be kept at room temperature in order to 
preserve the intermediate and the decomposition conditions must be carefully monitored. 
The optimal temperature for the reaction was between 55 and 60°C. 15 minutes were all 
it took for the reaction to go to completion; prolonged heating would result in 
decomposition of the dideoxy nucleoside. A 1:1 mixture of ethanol and water was used to 
provide the hydrogen source during workup. Formation of nitrogen gas bubbles in the 
solution was always a positive sign that the reaction was working.   
 
Scheme 4 
 
 
 
The other method attempted for the synthesis of dd2APy involves a dithioacetal 
intermediate 12 (Scheme 4). The dithioacetal compound was readily produced in high 
yield in the presence of a catalytic amount of trifluoroboron etherate. 9 The boron Lewis 
acid chelates to the carbonyl of the sugar moiety and thereby increases the 
electrophilicity of the carbonyl carbon. 1,2-ethanedithiol then masks the carbonyl as a 
dithioacetal functional group.  
Subsequent reduction by Raney nickel is also known as a desulfurization process 
as sulfur is removed from the dithioacetal compound. It is often done with a large excess 
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of Raney nickel (20 equivalents) in refluxing ethanol over a long period of time (at least 
24 hours).10 This method may be inappropriate for the synthesis of the dideoxynucleoside 
because nucleosides tend to be unstable at higher temperature especially when heated for 
a prolonged period of time. In addition, the use of hydrogen gas is not always required, 
although the solvent may provide a hydrogen source. The use of hydrogen gas in this 
reaction did not seem to help the process and a volume of relatively less polar solvent 
such as ethyl acetate was added to aid the solubility of the substrate. The Raney nickel 
generally used in the desulfurization reactions is freshly prepared as a W2 type.11 The 
procedure involves repetitive alternate washing of aqueous NaOH and water upon a 
nickel-aluminum alloy. Since Raney nickel is pyrophoric when dry and exposed to air, a 
commercially available Raney nickel product numbered 2800 was tested for this reaction 
for safety and convenience reasons. 12  According to the Sigma-Aldrich catalogue, 
however, this product is suitable as a hydrogenation catalyst for aromatic, olefin, nitrile 
and nitro group reductions. This might be the main factor contributing to the failure of 
this reduction reaction as the activity and hydrogen content may not be appropriate for 
this desulfurization reaction. These difficulties hampered the development of this new 
method to synthesize the dideoxynucleoside product and the method was therefore 
abandoned. 
 
Preparation and Purification of Triphosphates 
The dd2APy nucleoside and two products from the Heck coupling reactions with 
bases of FAPy and MAPy were converted into 5’-triphosphate derivatives. There are 
many approaches to synthesizing nucleoside triphosphates but not one universal method 
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to prepare all modified derivatives.13 Two synthetic procedures were compared and they 
differed only in the phosphorus activating reagent and workup. Ludwig and Eckstein 
developed a phosphite activating reagent 1314 which required an oxidation step (step 3) in 
the workup (Scheme 5). A less reactive phosphate activating reagent (POCl3) is also 
widely used (Scheme 6).15 Under either reaction condition, only the 5’ hydroxyl group is 
reactive toward the activating compound. Addition of pyrophosphate gives a temporary 
cyclic intermediate, which is then hydrolyzed to give the corresponding 5’-triphosphate 
derivative.  
 
Scheme 5  
 
 
 
 
The Ludwig-Eckstein method employs a highly reactive and hydroscopic 
phosphorus (III) activator 13. All solvents used in the method must be distilled one day 
ahead and stored in molecular sieves to ensure dryness. When performed carefully, the 
reaction could result in complete conversion to give the desired 5’-triphosphate derivative 
as indicated by a peak corresponding to product on an anion exchange column (Figure 
15). The dd2APy triphosphate was synthesized successfully. However, compounds 7 and 
8 were converted to monophosphates rather than triphosphates (data not shown). This 
suggests that the activated nucleoside might have been hydrolyzed prematurely due to the 
presence of water. Since the activating compound is a solid and taken out of the same 
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opened bottle for every use, water might have been introduced along with the addition of 
the reagent.  
 
 
Triphosphate 
 
Figure 15. HPLC chromatogram of the crude mixture of dd2APyTP from an anion 
exchange column. 
 
Scheme 6 
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1)  POCl3, (MeO)3PO, 
     Proton Sponge, 0-4°C, 3h 
2)  (HNBu3)2H2P2O7, DMF, 
      NBu3, 0-4°C, 15 min. 
3)  1M TEAB 
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 In order to avoid untimely hydrolysis, we opted to select a less reactive 
phosphorus (V) reagent, POCl3, for compounds 7 and 8. Since the reagent is a liquid, it 
was possible to distill it and seal it until ready to use. This minimizes the exposure of the 
activator to water and air. The downside of this approach is reduced reactivity of 
phosphorus (V). The nucleoside, though activated, reacts more slowly with 
pyrophosphate than the equivalent activated nucleoside in the Ludwig-Eckstein method. 
This results in incomplete conversion into triphosphate, as indicated by the presence of an 
almost 1:1 ratio of mono- versus triphosphate (Figure 16).  
 
Monophosphate Triphosphate 
 
Figure 16. HPLC chromatogram of the crude mixture of 15 from an anion exchange 
column.  
 
All three products were purified on HPLC first by an anion exchange column 
followed by a reverse phase column. They were characterized by 31P NMR (Figure 17) 
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and all had a signature peak near -22 ppm for the β-phosphorus atom, while the other two 
signals for α and γ phosphorus atoms occurred between -6 and -11 ppm depending on the 
pH and counterion.13  
Figure 17. Sample 31P NMR (300 MHz) of a nucleoside triphosphate. 
NH2
 
 
Future Plans 
 
One of the ultimate goals of this project is to investigate the role of minor groove 
interaction between the modified triphosphate substrate and the polymerase. The purified 
triphosphate derivatives will be tested in the future in various experiments, for example, 
enzyme-mediated DNA polymerization studies involving Pol α, Pol β, Pol γ, HIV-RT, 
and possibly other retroviruses. These studies will provide some insights into the nature 
and role of these minor groove interactions. What is most important – shape, size, 
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electronic effect, or hydrogen bonding requirement? If differential polymerase activity is 
observed for any of these triphosphate substrates, antiviral potentials will be examined.  
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Experimental Section 
 
 
5’-O-(4,4’-Dimethoxytrityl)thymidine (2) 
Thymidine (4 g, 16.5 mmol) was mostly dissolved in 40 
mL of pyridine after two co-evaporations with that solvent. 
4,4’-Dimethoxytrityl chloride (DMTr-Cl, 6.15 g, 18.2 
mmol) was added, along with 4-(dimethylamino)pyridine 
(DMAP, 0.10 g, 0.825 mmol) and triethylamine (3.21 mL, 23.1 mmol). The 
homogeneous solution was stirred at ambient temperature for 2 hours. After removing the 
solvents, the mixture was redissolved in ethyl ether and water for extraction. The water 
removed unreacted thymidine and DMAP, while all DMT-containing compounds 
remained in the ethyl ether layer. The organic layer was dried with sodium sulfate, 
concentrated, and purified on a silica gel column. The product was eluted with 3 % 
MeOH/CH2Cl2 in the presence of 0.5 % triethylamine. The product was a white foam 
(90%, 8g). 1H NMR was consistent with that previously reported.3 
O
N
O
HO
NH
O
O
OMe
MeO
 
 
3’-O-(t-Butyldiphenylsilyl)-5’-O-(4,4’-Dimethoxytrityl)-
thymidine (3) 
 
5’-O-DMT-thymidine (8 g, 14.7 mmol) and imidazole (2.5 
g, 36.7 mmol) were dissolved in 30 mL of DMF. t-
Butyldiphenylsilyl chloride (TBDPS-Cl, 4.2 mL, 16.4 
mmol) was added dropwise at lowered temperature. The reaction was complete overnight. 
The solvent was removed and dichloromethane and brine were added for extraction. The 
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organic layer was dried and concentrated to an appropriate volume for the next reaction 
without purification.  
 
 
3’-O-(t-Butyldiphenylsilyl)thymidine (4) 
5’-O-DMT-3’-O-TBDPS-thymidine (5 g, 6.4 mmol) was 
dissolved in a mixture of 60 mL dichloromethane and about 15 
mL methanol and cooled in an ice bath. 7 to 9 g of p-
toluenesulfonic acid were added to drive the reaction to 
completion over the course of up to 1 hour. The acid was removed by washing with 5 % 
Na2CO3 solution twice. The organic layer was dried and concentrated to give a thick oil. 
The product was eluted with 40 % ethyl acetate in hexanes. It was a white foam (3g, 95 
%). 1H NMR was consistent with that previously reported. 3 
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1,2-Dehydro-3-O-(t-butyldiphenylsilyl)-5-hydroxymethyl-furan (5) 
3’-O-TBDPS-thymidine (3.5 g, 7.3 mmol) was combined with 
ammonium sulfate (0.26 g, 2.0 mmol). 30 mL of 1,1,1,3,3,3-
hexamethyldisilazane (HMDS) were injected into the refluxing 
apparatus. The mixture was heated at 140°C for 2 hours. Solvent was 
removed to give a thick cloudy mixture. 50 mL of methanol were added to produce a 
white suspension. At 0°C, 1.1 g of K2CO3 was added. After 30 minutes, the mixture was 
filtered through a thin layer of Celite. Solvents were removed to give a thick cloudy 
mixture again, which was immediately purified by silica gel with straight CH2Cl2. The 
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product was a clear oil (80 %, 2.8 g). 1H NMR was consistent with that previously 
reported. 3 
 
 
5(β-D-glyceropentofuran-3’-ulos-1’)-2-amino-pyridine (6) 
A mixture of tris(dibenzylideneacetone)dipalladium(0) (232 mg, 
0.25 mmol) and pentafluorotriphenylphosphine (270 mg, 0.57 mmol) 
was stirred in 50 mL of acetonitrile at ambient temperature for 5 
hours. It turned orange brown. Then a solution of the sugar 5 (1.0 g, 2.8 mmol) in 15 mL 
of acetonitrile from the previous step was injected into the catalyst mixture. 2-amino-5-
iodo-pyridine (838 mg, 3.8 mmol) was added as a solid. N,N-diisopropylethylamine (126 
μl, 0.72 mmol) was injected. After 48 hours of refluxing at 80°C, when the sugar was 
mostly consumed, the mixture was filtered through a thin layer of Celite. The brown 
filtrate was concentrated to a brown oil. The oil was dissolved in 5 mL of THF and 
cooled in an ice bath. Acetic acid (0.05 mL, 0.87 mmol) and 0.7 mL (2.4 mmol) of 1M 
tetrabutylammonium fluoride in THF were added. The brown solution was stirred on ice 
for 30 minutes. Solvents were removed and the product was eluted with 5 % 
MeOH/CH2Cl2 (1.0 g, 85 %). 1H NMR was consistent with that previously reported.2 
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6-Amino-3-(β-D-glycero-pentofuran-3’-ulos-1’yl)-2-
fluoropyridine (7) 
 
A mixture of tris(dibenzylideneacetone)dipalladium(0) (348 mg,  
0.38 mmol) and pentafluorotriphenylphosphine (810 mg, 1.5 mmol) 
was stirred in 50 mL of acetonitrile at ambient temperature for 5 
hours. It turned orange brown. Then a solution of the sugar 5 (672 mg, 1.9 mmol) in 15 
mL of acetonitrile from the previous step was injected into the catalyst mixture. 6-amino-
2-fluoro-3-iodopyridine (300 mg, 2.3 mmol) was added as a solid. N,N-
diisopropylethylamine (198 μl, 1.1 mmol) was injected. After 48 hours of refluxing at 
85°C, when the heterocycle was mostly consumed, the mixture was filtered through a 
thin layer of Celite. The brown filtrate was concentrated to a brown oil. The oil was 
dissolved in 5 mL of THF and cooled in an ice bath. Acetic acid (0.05 mL, 0.87 mmol) 
and 0.3 mL (1.1 mmol) of 1M tetrabutylammonium fluoride in THF were added. The 
brown solution was stirred on ice for 30 minutes. Solvents were removed and the product 
was eluted with 1.5 % MeOH/CH2Cl2 (133 mg, 59 %). 1H NMR was consistent with that 
previously reported.2 
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6-Amino-3-(β-D-glycero-pentofuran-3’-ulos-1’yl)-2-
methylpyridine (8) 
 
A mixture of bis(dibenzylideneacetone)palladium(0) (128 mg,  
0.22 mmol) and pentafluorotriphenylphosphine (426 mg, 0.80 
mmol) was stirred in 50 mL of acetonitrile at ambient 
temperature for 5 hours. It turned orange brown. Then a solution of the sugar 5 (830 mg, 
2.3 mmol) in 15 mL of acetonitrile from the previous step was injected into the catalyst 
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mixture. 6-amino-2-methyl-3-iodopyridine (262 mg, 2.1 mmol) was added as a solid. 
N,N-diisopropylethylamine (389 μl, 2.2 mmol) was injected. After 48 hours of refluxing 
at 90-95°C, when the heterocycle was mostly consumed, the mixture was filtered through 
a thin layer of Celite. The brown filtrate was concentrated to a brown oil. The oil was 
dissolved in 5 mL of THF and cooled in an ice bath. Acetic acid (0.05 mL, 0.87 mmol) 
and 0.3 mL (1.1 mmol) of 1M tetrabutylammonium fluoride in THF were added. The 
brown solution was stirred on ice for 30 minutes. Solvents were removed and the product 
was eluted with 5 % MeOH/CH2Cl2 (150 mg, 29 %). 1H NMR was consistent with that 
previously reported.2 
 
 
 
6-[2-(4-Nitrophenlethoxy)]-3-(β-D-glyceropentofuran-
3’-ulos-1’yl)-2-fluropyridine (9) 
 
A mixture of bis(dibenzylideneacetone)palladium(0) 
(128 mg,  0.22 mmol) and pentafluorotriphenyl-
phosphine (426 mg, 0.80 mmol) was stirred in 50 mL of 
acetonitrile at ambient temperature for 5 hours. It turned 
orange brown. Then a solution of the sugar 5 (830 mg, 2.3 mmol) in 15 mL of acetonitrile 
from the previous step was injected into the catalyst mixture. 6-(4-nitrophenylethoxy)-2-
fluoro-3-iodopyridine (433 mg, 1.1 mmol) was added as a solid. N,N-
diisopropylethylamine (389 μl, 2.2 mmol) was injected. After 48 hours of refluxing at 
90°C, when the heterocycle was mostly consumed, the mixture was filtered through a 
thin layer of Celite. The brown filtrate was concentrated to a brown oil. The oil was 
dissolved in 5 mL of THF and cooled in an ice bath. Acetic acid (0.05 mL, 0.87 mmol) 
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and 0.3 mL (1.1 mmol) of 1M tetrabutylammonium fluoride in THF were added. The 
brown solution was stirred on ice for 30 minutes. Solvents were removed and the product 
was eluted with 0.5 % MeOH/CH2Cl2 (200 mg, 23 %). 1H NMR was consistent with that 
reviously reported.2 
ophenlethoxy)]-3-(β-D-glyceropentofuran-
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6-[2-(4-Nitr
3’-ulos-1’yl)-2-methylpyridine (10) 
A mixture of tris(dibenzylideneacetone)dipalladium(0) 
(150 mg,  0.16 mmol) and pentafluorotriphenyl-
phosphine (120 mg, 0.23 mmol) was stirred in 50 mL of 
acetonitrile at ambient temperature for 5 hours. It turned 
orange brown. Then a solution of the sugar 5 (500 mg, 1.4 mmol) in 15 mL of acetonitrile 
from the previous step was injected into the catalyst mixture. 6-(4-nitrophenylethoxy)-3-
iodo-2-methylpyridine (800 mg, 2.1 mmol) was added as a solid. N,N-
diisopropylethylamine (100 μl, 0.57 mmol) was injected. After 48 hours of refluxing at 
90°C, when the heterocycle was mostly consumed, the mixture was filtered through a 
thin layer of Celite. The brown filtrate was concentrated to a brown oil. The oil was 
dissolved in 5 mL of THF and cooled in an ice bath. Acetic acid (0.05 mL, 0.87 mmol) 
and 0.3 mL (1.1 mmol) of 1M tetrabutylammonium fluoride in THF were added. The 
ed on ice for 30 minutes. Solvents were removed and the product 
eOH/CH2Cl2 (200 mg, 23 %). 1H NMR was c
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5-(β-D-glyceropentofur
 
product precipitate was collected 
an-3’-ulos-1’-yl)-2-aminopyridine p-
and the filtrate was subjected 
 silica gel column. More product was eluted with 5 % MeOH/CH2Cl2 (total 300 mg, 83 
). 1H NMR was consistent with that previously reported.4a 
5(β-D-glyceropentofuran-2’,3’-dideoxy-1’)-2-amino-pyridine 
 
n was heated at 55-60°C for 15 min. to give a darker yellow solution. The 
product was elute viously 
reported.4a 
O
NH2
toluenesulfonylhydrazone (11) 
Compound 6 (200 mg, 0.96 mmol) was suspended in about 4 
mL of freshly distilled methanol. p-Toluenesulfonylhydrazide 
(0.54 g, mmol) was added. The mixture was stirred at ambient 
temperature overnight. The reaction was monitored by alumina 
TLC plate. Rf :0.2 (5 % methanol in dichloromethane). The 
to
%
 
 
 
(dd2APy) 
The hydrazone (300 mg, mmol ) was suspended in 4 mL of dry 
acetonitrile. About 3 mL of acetic acid were added dropwise at 0°C. 
The slurry was stirred to gradually turn clear. NaBH4 (60 mg, mmol) 
was added in 2 portions over a 45 min. period. The reduction step was over as indicated 
by the disappearance of starting material and the appearance of a slower running spot. 
About 1-2 mL of water was used to quench the reaction; bubbles evolved and stopped. 
Solvents were evaporated at ambient temperature, using ethanol to coevaporate the acid. 
The resulted yellow oil was redissolved in 3 mL of a 1:1 mixture of ethanol and water. 
The solutio
d with 5% MeOH/CH2Cl2. 1H NMR was consistent with that pre
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(8-(6-aminopyridin-3-yl)-7-oxa-1,4-dithiaspiro[4.4]nonan-6-
 
1
13
O
yl)methanol (12) 
Compound 6 (230 mg, 1.1 mmol) was dissolved in 15 mL of CH2Cl2. 
the yellow solution was cooled to -78°C. BF3 · Et2O (0.68 mL, 5.55 
mmol) was added dropwise. 1,2-ethanedithiol (3.3 mL, 2.8 mmol) was 
added to give an orange mixture. The mixture was stirred at -78°C for 30 minutes then at 
ambient temperature overnight. The solution turned clear and light yellow. Solvents 
including1,2-ethanedithiol was removed on vacuum. The product was eluted with 2 % 
MeOH/CH2Cl2 with 0.5 % TEA. The product was a solid (300 mg, 96%). Rf (7 % 
MeOH/CH2Cl2) = 0.31. H NMR (CDCl3) δ = 2.45 (dd, 1H), 2.75 (dd, 1H), 3.34 (m, 2H), 
3.38 (m, 2H), 3.85 (d, 2H), 4.20 (m, 1H), 4.45 (b, 2H), 4.90 (m, 1H), 6.50 (d, 1H), 7.50 (d, 
1H), 8.03 (s, 1H). C NMR (CD3OD/CHCl3) δ = 39.8, 41.1, 54.7, 64.6, 71.1, 78.8, 79.5, 
90.1, 110, 127, 139, 146. Exact mass calculated for [C12H16N2O2S2] requires 284.07; 
5’-Triphosphate derivative of dd2APy (14) 
The dideoxynucleosides dd2APy (15 mg, 0.077 mmol) 
was coevaporated with pyridine twice and dried in a 
desiccator for at least 1 h. 77 μl of pyridine and 231 μl of freshly distilled dioxane were 
added to dissolve the starting material. 77 μl of a 1M solution of 2-Cl-
benzodioxaphosphorin-4-one in dioxane were added. Precipitation occurred as the 
pyridine precipitated with chloride. 30 min. later, 231 μl of a 0.5 M solution of 
tetrabutylammonium pyrophosphate in DMF were injected. The mixture turned very 
cloudy until 77 μl of dry tributylamine was added. 40 min. later, 2 mL of 1% I2 in 98:2 
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found, 284.6227 (ESI+). 
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pyridine:water mixture were added for oxidation. After 20 min., solvents were removed 
on high vacuum to give an oil. Ether and water extractions resulted in yellow layers. The 
aqueous one was concentrated and filtered for HPLC purification. The mixture was first 
separated on an anion-exchange column to isolate the triphosphate using a 30 min. 
gradient of 0 – 100% Buffer B. Buffer A was deionized water and Buffer B was 1M 
triethylammonium bicarbonate (TEAB). After concentration of the fractions, the sample 
was desalted on a reverse phase column using a 15 min. gradient of 0 – 100 % Buffer B. 
Buffer A was 50 mM triethylammonium acetate (TEAA) pH 7.0 in 2 % methanol. Buffer 
B contained the same salt concentration with 50 % methanol. The product was 
oncentrated and coevaporated with water a few times on the lyophilizer. λmax (H2O) = 
90 nm. 31P NMR (300 MHz, D2O) δ = -9 (d, 1P), -7 (d, 1P), -22 (t, 1P).  
5’-Triphosphate derivative of 7 (15) 
c
2
 
 
The nucleoside 7 (18 mg, 0.080 mmol) was 
coevaporated with acetonitrile twice to give a yellow 
foam and dried in a desiccator overnight. It was 
dissolved in trimethylphosphate (380 μl) at 0-4°C. 10% proton sponge (2 mg) and freshly 
distilled POCl3 (18.2 μl, 0.080 mmol) were added at once. The brown solution turned 
slightly darker in color. 3 h. later, all starting material was consumed. A solution of bis-
tributylammonium pyrophosphate (0.5 M in DMF, 0.86 mL, 0.43 mmol) and 
tributylamine (200 μl, 0.84 mmol) were added quickly. The reaction was quenched 15 
min. later with 1 M triethylammonium bicarbonate buffer (TEAB, pH 7.5, about 6 mL). 
Solvents were removed, using ethanol for a few coevaporations. The resulted solid was 
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redissolved in water. The yellow solution was filtered and purified on HPLC. The 
purification process on the ion exchange column was the same as that described for 14.  
he sample still remains to be desalted on a reverse phase column. λmax (H2O) = 290 nm. 
P NMR (300 MHz, D2O) of the pre-desalted sample δ = -10, -22 .  
urification process 
n the ion exchange column was the same as that described for 14. λmax (H2O) = 290 nm. 
P NMR (300 MHz, D2O) δ = -9.5 (1P, d), -10.5 (1P, d), -22 (1P, t).  
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5’-Triphosphate derivative of 8 (16) 
The nucleoside 8 (33 mg, 0.135 mmol) was 
coevaporated with acetonitrile twice to give a 
yellow foam and dried in a desiccator overnight. It 
was dissolved in trimethylphosphate (675 μl) at 0-4°C. 10% proton sponge (2 mg) and 
freshly distilled POCl3 (31 μl, 0.35 mmol) were added at once. The brown solution turned 
slightly darker in color. 3 h. later, all starting material was consumed. A solution of bis-
tributylammonium pyrophosphate (0.5 M in DMF, 1.3 mL, 0.65 mmol) and tributylamine 
(338 μl, 1.60 mmol) were added quickly. The reaction was quenched 15 min. later with 1 
M triethylammonium bicarbonate buffer (TEAB, pH 7.5, about 10 mL). Solvents were 
removed, using ethanol for a few coevaporations. The resulted solid was redissolved in 
water. The yellow solution was filtered and purified on HPLC. The p
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